PRRX2

Across TCGA pan-cancer cohorts, PRRX2 mass-spec protein differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of PRRX2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where PRRX2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PRRX2 is over-expressed in tumor, although a few such as HNSC show the opposite, repressed pattern.

LUAD and HNSC are the cancer types where PRRX2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRRX2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	All	+0.534	.006	4	view →
HNSC	All	All	−0.238	.030	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

PRRX2–LUAD

Open the LUAD breakdown →